These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 35369354)

  • 41. An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline.
    Chang WT; Liu CF; Feng YH; Liao CT; Wang JJ; Chen ZC; Lee HC; Shih JY
    Arch Toxicol; 2022 Oct; 96(10):2731-2737. PubMed ID: 35876889
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
    Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
    Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity.
    Galán-Arriola C; Lobo M; Vílchez-Tschischke JP; López GJ; de Molina-Iracheta A; Pérez-Martínez C; Agüero J; Fernández-Jiménez R; Martín-García A; Oliver E; Villena-Gutierrez R; Pizarro G; Sánchez PL; Fuster V; Sánchez-González J; Ibanez B
    J Am Coll Cardiol; 2019 Feb; 73(7):779-791. PubMed ID: 30784671
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiac MRI Myocardial Functional and Tissue Characterization Detects Early Cardiac Dysfunction in a Mouse Model of Chemotherapy-Induced Cardiotoxicity.
    Naresh NK; Misener S; Zhang Z; Yang C; Ruh A; Bertolino N; Epstein FH; Collins JD; Markl M; Procissi D; Carr JC; Allen BA
    NMR Biomed; 2020 Sep; 33(9):e4327. PubMed ID: 32567177
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nuclear imaging in detection and monitoring of cardiotoxicity.
    D'Amore C; Gargiulo P; Paolillo S; Pellegrino AM; Formisano T; Mariniello A; Della Ratta G; Iardino E; D'Amato M; La Mura L; Fabiani I; Fusco F; Perrone Filardi P
    World J Radiol; 2014 Jul; 6(7):486-92. PubMed ID: 25071889
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.
    Ferreira de Souza T; Quinaglia A C Silva T; Osorio Costa F; Shah R; Neilan TG; Velloso L; Nadruz W; Brenelli F; Sposito AC; Matos-Souza JR; Cendes F; Coelho OR; Jerosch-Herold M; Coelho-Filho OR
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1045-1055. PubMed ID: 30092965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early Detection and Serial Monitoring of Anthracycline-Induced Cardiotoxicity Using T1-mapping Cardiac Magnetic Resonance Imaging: An Animal Study.
    Hong YJ; Park HS; Park JK; Han K; Park CH; Kim TK; Yoo SJ; Lee JY; Kim PK; Hur J; Lee HJ; Kim YJ; Suh YJ; Paek MY; Choi BW
    Sci Rep; 2017 Jun; 7(1):2663. PubMed ID: 28572614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multiparametric Cardiovascular Magnetic Resonance Approach in Diagnosing, Monitoring, and Prognostication of Myocarditis.
    Eichhorn C; Greulich S; Bucciarelli-Ducci C; Sznitman R; Kwong RY; Gräni C
    JACC Cardiovasc Imaging; 2022 Jul; 15(7):1325-1338. PubMed ID: 35592889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling.
    Tham EB; Haykowsky MJ; Chow K; Spavor M; Kaneko S; Khoo NS; Pagano JJ; Mackie AS; Thompson RB
    J Cardiovasc Magn Reson; 2013 Jun; 15(1):48. PubMed ID: 23758789
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Laursen AH; Thune JJ; Hutchings M; Hasbak P; Kjaer A; Elming MB; Ripa RS
    Clin Physiol Funct Imaging; 2018 Mar; 38(2):176-185. PubMed ID: 28251781
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy.
    Huang W; Xu R; Zhou B; Lin C; Guo Y; Xu H; Guo X
    Front Cardiovasc Med; 2022; 9():912329. PubMed ID: 35757327
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cellular Mechanisms Mediating Exercise-Induced Protection against Cardiotoxic Anthracycline Cancer Therapy.
    Dozic S; Howden EJ; Bell JR; Mellor KM; Delbridge LMD; Weeks KL
    Cells; 2023 May; 12(9):. PubMed ID: 37174712
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods.
    Soufer A; Liu C; Henry ML; Baldassarre LA
    J Nucl Cardiol; 2020 Aug; 27(4):1210-1224. PubMed ID: 30868378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: cardiovascular magnetic resonance and nuclear cardiology.
    Pepe A; Pizzino F; Gargiulo P; Perrone-Filardi P; Cadeddu C; Mele D; Monte I; Novo G; Zito C; Di Bella G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e45-e54. PubMed ID: 27755242
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chronic Anthracycline-related Myocarditis Presenting as Diffuse Myocardial Calcification.
    Pejic M; Shifman M; Rose T; Jeong D
    J Clin Imaging Sci; 2019; 9():47. PubMed ID: 31819824
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiac imaging in cardiotoxicity: a focus on clinical practice.
    Makavos G; Ikonomidis I; Palios J; Rigopoulos A; Katogiannis K; Parissis J; Paraskevaidis I; Noutsias M
    Heart Fail Rev; 2021 Sep; 26(5):1175-1187. PubMed ID: 32306221
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
    Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
    BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumab.
    Gulati G; Zhang KW; Scherrer-Crosbie M; Ky B
    Curr Heart Fail Rep; 2014 Dec; 11(4):366-73. PubMed ID: 25079445
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity.
    Buck B; Chum AP; Patel M; Carter R; Nawaz H; Yildiz V; Ruz P; Wiczer T; Rogers KA; Awan FT; Bhat S; Guha A; Kittai AS; Simonetti OP; Raman SV; Wallace G; Sanchez R; Bonsu JM; Gambril J; Haddad D; Mann J; Wei L; Kola-Kehinde O; Byrd JC; Woyach JA; Addison D
    JAMA Oncol; 2023 Apr; 9(4):552-555. PubMed ID: 36729480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.